Metoclopramide Baxter (Metoclopramide Hydrochloride)

Metoclopramide works by selectively blocking dopamine D2 receptors in the chemoreceptor trigger zone and throughout the gastrointestinal tract. This blockade lifts dopaminergic inhibition, increases acetylcholine release, and stimulates smooth‑muscle contraction, leading to faster gastric emptying and a central anti‑emetic effect.

The dose of Metoclopramide Baxter is determined by the prescribing clinician based on the specific indication, severity of symptoms, patient weight, renal function, and treatment duration. Only a qualified health professional should set the appropriate dosing regimen.

Safety data for Metoclopramide in pregnancy and lactation are limited, and the product’s pregnancy category is not definitively established. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing patients.

To order Metoclopramide Baxter, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Metoclopramide differs from serotonin‑based antiemetics such as ondansetron by targeting dopamine receptors rather than serotonin receptors. It also has pro‑kinetic activity, which can be advantageous in gastroparesis, whereas drugs like ondansetron lack this effect. However, Metoclopramide carries a higher risk of extrapyramidal side effects with prolonged use.

Metoclopramide Baxter should be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Follow standard aseptic techniques when preparing for injection.

Metoclopramide Baxter is supplied as an injectable solution for intramuscular or intravenous administration. The medication is typically drawn into a sterile syringe and given as a slow IV push or IM injection, according to the prescriber’s instructions and the clinical setting.

The most serious risks include tardive dyskinesia, a potentially irreversible movement disorder that can develop with prolonged use, and neuroleptic malignant syndrome, a rare but life‑threatening reaction characterized by fever, muscle rigidity, and autonomic instability. Prompt medical attention is required if these symptoms appear.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, in infants younger than one month, and in individuals with a history of severe extrapyramidal reactions. Caution is also advised for patients with Parkinson’s disease, uncontrolled epilepsy, or significant cardiovascular disease.